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depression and anxiety and also sexual problems com-
pared to healthy subjects.
Conclusions FHA patients should be carefully diagnosed 
and properly managed to prevent both short- and long-term 
medical consequences.
Keywords Hypothalamic amenorrhea · Gonadotropin-
releasing hormone · Bone mass density · Cardiovascular 
system · Sexual problems
Introduction
Definition
Functional hypothalamic amenorrhea (FHA) is classified 
as hypogonadotropic hypogonadism related to an aber-
ration of the pulsatile release of gonadotropin-releasing 
hormone (GnRH) from the hypothalamus [1, 2]. The spec-
trum of hypothalamic–pituitary disturbances in FHA may 
be very broad and includes a lower mean frequency of LH 
pulses, the complete absence of LH pulsatility, as well 
as a normal-appearing secretion pattern and higher mean 
frequency of LH pulses [3]. In turn, decreased gonadotro-
pin secretion leads to reduced estradiol production in the 
ovary. The disturbed hypothalamic–pituitary-ovarian axis 
in FHA cases is associated typically with stress, weight 
loss and/or excessive physical exercise and is one of the 
most common causes of secondary amenorrhea. Depend-
ing on the eliciting factor, there are three classes of FHA: 
weight loss related, stress related and exercise related [4].
Regardless of the specific trigger, a complex state of 
hypoestrogenism, other endocrinological aberrations and 
metabolic abnormalities due to FHA may impact the whole 
body homeostasis [5].
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Epidemiology
Secondary amenorrhea, which is defined as 3 months 
absence of menstruation, occurs in approximately 3–5 % of 
adult women. According to the American Society of Repro-
ductive Medicine, FHA is responsible for 20–35 % of sec-
ondary amenorrhea cases and approximately 3 % of FHA 
cases of primary amenorrhea [6]. The incidence is higher in 
athlete women. DeSouza et al. [7] estimated that approxi-
mately 50 % of women who exercise regularly experience 
subtle menstrual disorders and approximately 30 % of 
women have amenorrhea. The complex of distorted eating, 
amenorrhea and osteoporosis was first described in 1997 
and is known as female athlete triad [8].
Differential diagnosis
Functional hypothalamic amenorrhea should be, in each 
case, differentiated from other forms of primary or second-
ary amenorrhea. The basic approach to this distinction is 
an assessment of the gonadotropins and identifying hypo-
gonadotrophic hypogonadism [6]. If such a diagnosis has 
been made, the key diagnostic tool is a GnRH stimulation 
test, which in the case of FHA shows a positive response 
of the gonadotropins to exogenous GnRH. This test eas-
ily distinguishes hypothalamic dysfunction from pituitary 
diseases, where hypogonadism is also characteristic [4, 6]. 
Once the hypothalamic origin has been found, it is impor-
tant to rule out genetic and organic diseases. As a potential 
cause of amenorrhea of genetic origin, the following should 
be taken into account: Kallman syndrome (characterized by 
anosmia, specific mutations), Prader–Willi syndrome (with 
characteristic hyperorxia, obesity, retardation) and other 
rare syndromes with idiopathic hypogonadotropic hypog-
onadism [3, 6, 9]. Features such as delayed puberty, primary 
amenorrhea and the presence of additional symptoms (anos-
mia, mental retardation, extreme obesity, facial dysmorphia, 
malabsorption) are suggestive of congenital diseases [6, 9]. 
To rule out organic diseases of the hypothalamic area (neo-
plasms, sarcoidosis, tuberculosis, parasitoids and other infil-
trating lesions) imaging evaluation might be helpful [6].
Hormonal disturbances associated with FHA
As described above, FHA results from depression of the 
hypothalamic–pituitary–ovarian axis. Impairment of GnRH 
and gonadotrophin secretion as a sequel is the key pathol-
ogy in this trait, and also other pituitary hormone secretion 
is abnormal in FHA.
A typical feature of FHA is hypothalamic–pituitary–adrenal 
axis activation, related to stressing factors, and this phenom-
enon is believed to be one of the important pathogenetic fac-
tors in FHA patients [4, 10]. Increased corticotropin-releasing 
hormone (CRH) secretion results in an increased secretion of 
adrenocorticotrophin from the pituitary and cortisol from the 
adrenal glands, and these phenomena are linked to a reduced 
GnRH drive. Elevated serum and also cerebrospinal cortisol 
concentrations have been reported in FHA [9].
Disturbances in the hypothalamic–pituitary–thyroid axis 
in FHA patients are also observed. They include a low-to-
normal level of thyrotropin, an increased level of reverse 
triiodothyronine and a low level of triiodothyronine [2].
Other findings related to hypothalamic amenorrhea 
include elevated nighttime serum growth hormone levels 
and lower 24 h prolactin levels [11]. FHA patients are char-
acterized by low serum insulin and insulin-like growth fac-
tor 1 (IGF-1) and increased insulin sensitivity [10]. Besides 
this, androgen levels are known to be lower in FHA patients 
in comparison to healthy controls.
Clinically, FHA should not be understood only as a 
symptom such as amenorrhea. This disorder has a more 
thought-provoking clinical image [2–4]. The final endo-
crinological consequence of impairment in GnRH and gon-
adotropin pulsatile secretion is profound hypoestrogenism. 
Hypoestrogenic status has a negative influence on different 
aspects of female health, not only in menopausal women 
but also in young individuals [2–4]. Moreover, hormo-
nal disturbances are accompanied by metabolic disorders 
related to FHA causative factors, i.e., negative energetic 
balance and stress [1–5].
Particularly in young women, normoestrogenism and 
metabolic homeostasis have a critical significance for nor-
mal bone metabolism, the cardiovascular system and men-
tal health. Therefore, prolonged hypoestrogenism which 
occurs in young women may have important consequences 
on women’s future health.
Neuroendocrine alterations in FHA
The precise mechanisms underlying the pathophysiology of 
FHA are very complex and unclear. Numerous neuropep-
tides, neurotransmitters and neurosteroids play an impor-
tant role in the physiological regulation of GnRH pulsatile 
secretion and there is evidence that these substances may 
be involved in the pathophysiology of FHA [12]. Particular 
attention should be paid to such substances as kisspeptin, 
neuropeptide Y (NPY), ghrelin, leptin, corticotropin-releas-
ing hormone (CRH), b-endorphin and allopregnanolone.
Kisspeptin, the product of the KiSS-1 gene and its G 
protein-coupled receptor GPR54, plays a master role in the 
puberty period and fertility [13]. The kisspeptin/GPR54 
system activates the hypothalamus–pituitary–ovarian axis. 
Kisspeptin can directly stimulate GnRH secretion from the 
arcuate nucleus of the hypothalamus [14]. Administration 
of exogenous kisspeptin causes an increase of serum LH 
and FSH in healthy females. Kisspeptin administered in an 
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acute way to women with FHA potently stimulates gonado-
tropin release [15].
Neuropeptide Y (NPY) acts as a regulator of energy 
balance, sexual behavior and circadian rhythm [16]. NPY 
affects the appetite center in the hypothalamus and stimu-
lates feeding behavior [17]. NPY induces the production 
of GnRH if the concentrations of sex steroids, mainly 
estradiol, are high enough. An inhibitory effect of NPY on 
GnRH is observed in hypoestrogenic subjects [18]. Mecze-
kalski et al. [19] observed lower basal serum NPY in amen-
orrheic patients than in menstruating women. The numbers 
of NPY and LH peaks were higher in patients with weight 
loss-related amenorrhea than in controls.
Ghrelin is a peptide that stimulates appetite, but reduces 
fat utilization [20]. Additionally, ghrelin inhibits the hypo-
thalamic–pituitary–gonadal axis and is responsible for the 
prolongation of amenorrhea in subjects who have regained 
normal weight [21]. Women with FHA are characterized by 
elevated ghrelin levels compared with healthy women [22]. 
Exercising or underweight amenorrheic patients are char-
acterized by a significantly greater serum ghrelin elevation 
than those who remain with stable weight [23].
Leptin is an adipose tissue-derived hormone which plays 
a crucial role in the link between metabolic and hormo-
nal signals and their impact on the reproductive axis [24]. 
Patients suffering from hypothalamic amenorrhea are char-
acterized by considerably lower serum leptin concentra-
tions compared with age-, weight- and body fat-matched 
eumenorrheic controls [25].
CRH plays an important role in the regulation of repro-
duction by modulating the hypothalamus–pituitary–adrenal 
axis as well as the hypothalamus–pituitary–ovary axis [26]. 
Physical or mental stress activates an instant increase of 
CRH in the CNS. Subsequently, CRH stimulates the pitui-
tary secretion of ACTH and other pro-opiomelanocortin 
(POMC)-related peptides such as beta-endorphin and 
b-lipotropic hormone. Increased secretion of glucocorti-
costeroids inhibits the release of GnRH and gonadotropins. 
These described mechanisms suggest a specific stress etiol-
ogy of hypothalamic amenorrhea [27].
Beta-Endorphin is an endogenous neuropeptide, found 
in the hypothalamus and pituitary gland, playing a sig-
nificant role in the etiopathophysiology of hypothalamic 
amenorrhea [28]. This effect is based on the disturbed 
GnRH production and thus impaired LH release. CRH may 
directly inhibit GnRH secretion and stimulate beta-endor-
phin production in the case of stress-related and exercise-
related amenorrhea. These two conditions are characterized 
by increased opioidergic activity in stress- and exercise-
related amenorrhea [27].
Allopregnanolone is a neurosteroid acting as an endog-
enous modulator of excitability of the CNS [29]. Patients 
suffering from hypothalamic amenorrhea demonstrate a 
considerable episodic release of allopregnanolone. This spe-
cific pulsatile secretion is similar in frequency and amplitude 
to that in fertile women. However, a higher pulse amplitude 
of allopregnanolone is demonstrated in amenorrheic patients 
than in controls. Likewise, higher plasma allopregnanolone 
levels are observed in amenorrheic subjects [30].
Reproduction
Functional hypothalamic disturbances and neuroendocrine 
aberrations have both short- and long-term consequences for 
reproductive health. Understandably, an impaired or dimin-
ished hypothalamic-pituitary–ovarian axis leads to anovulation 
and hypoestrogenism. Lack of cyclical changes of estradiol 
and progesterone concentrations leads to abolished endome-
trial cyclicity and typically endometrium is in the persistent 
early profilerative phase. Anovulation is directly linked to the 
neurohormonal and hormonal background of FHA. Impair-
ment of pulsatile GnRH secretion causes the impairment of 
pulsatile LH and FSH secretion. The final consequence is pro-
found hypoestrogenism which determines anovulation [31]. If 
the disturbance appears during puberty, women present with 
primary amenorrhea. Secondary amenorrhea, which is more 
common in FHA, develops in postpubertal girls and women.
According to Hind [31], proper diagnosis and treatment 
of FHA are important due to the potential risk of infertil-
ity arising from chronic amenorrhea. Devoto and Aravena 
[32] found that in teenagers with hypothalamic dysfunction 
and menstrual disturbances, a deficient or bad response to 
clomiphene does not necessarily indicate a bad prognosis in 
terms of menses or fertility.
As stated before, anovulation is a characteristic feature 
of FHA, so those patients who suffer from this condition 
are unable to become spontaneously pregnant—a fact that 
is well established [33]. Another issue is how long lasting 
untreated hypothalamic amenorrhea influences reproduc-
tive health in the future. Delayed menarche, dyschronic 
puberty and the underdevelopment of secondary and ter-
tiary sex characteristics are potential obstacles to reproduc-
tive health in girls affected by FHA during puberty. In adult 
women, the same disease can lead to atrophic changes in 
the urogenital mucosa and in the muscles of the uterus.
However, if a patient with FHA or with a history of FHA 
becomes pregnant, this pregnancy requires special care due 
to the increased risk of miscarriage and preterm labor [34]. 
Additionally, patients with FHA can present more obstetric 
complications such as impaired weight gain and compro-
mised intrauterine fetal growth [35].
Shen ZQ et al. [36] studied factors affecting menstrual 
resumption and estimated the pituitary response to GnRH 
in functional hypothalamic amenorrhea. They recruited 
to the study 30 cases with FHA and treated them with 
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continuous 1 mg/day estradiol valerate orally. The occur-
rence of at least three consecutive regular cycles was 
seen in the majority of FHA women undertaking estro-
gen replacement therapy. The likelihood of recovery was 
affected by their BMI beforehand and by amenorrhea, but 
not by weight gain during therapy. The menstrual resump-
tion in FHA was accompanied by the recovery of serum 
LH and the LH response to GnRH [32].
Bone health
FHA exerts a negative influence on the skeletal system. 
It is related to a great extent to the failure to achieve 
peak bone mass (PBM) [33]. PBM is defined as the larg-
est amount of bone tissue that a person has at any point 
in life [37]. Most people reach their peak mass by the 
age of 30 years, but approximately 40–50 % of PBM is 
formed during the puberty period [33]. Hormonal and 
nutritional factors contribute 40–60 % and genetic fac-
tors 60–80 % in constituting PBM [38]. Sex steroids 
(estrogens, androgens), growth hormone (GH) and insu-
lin growth-like 1 (IGF1) are the main hormones which 
exert a positive influence on PBM formation [39]. In 
young women, estrogens are the critical determinants 
which ensure proper bone metabolism [40]. Estro-
gen action is performed in three directions: the activa-
tion of bone remodeling units, the suppression of bone 
resorption and the stimulation of bone formation [41]. 
Estrogens stimulate synthesis of the main growth fac-
tors such as transforming growth factor beta-TGF-beta, 
bone morphogenetic protein 6-BMP6 and insulin-like 
growth factor 1-IGF-1. Estrogens are also responsi-
ble for 1,25(OH)D3 expression receptors increase [42]. 
Additionally, estrogen can exert an influence on the inhi-
bition of RANKL production (the receptor activator of 
nuclear factor kappa B ligand) and an increase of osteo-
protegerin gene expression (the inhibitor of osteoclasts 
formation). Moreover, estrogens are responsible for the 
decrease of proresorptive cytokins’ synthesis such as 
macrophage-colony stimulating factor (M-CSF), inter-
leukin-6 (IL-6), interleukin-1, (IL-1) and tumor necrosis 
factor α (TNF-α) [43]. Therefore, prolonged hypoestro-
genism in young women with FHA is associated with 
osteopenia and osteoporosis risk.
The minimal serum estradiol level, which has a posi-
tive impact on bone metabolism, is 40–50 pg/ml [44]. 
According to the literature and clinical practice, serum 
estradiol levels in patients with FHA are below 20 pg/ml 
[36]. Patients with FHA are threatened by a low PBM 
not only due to hypoestrogenism. Other important factors 
include improper diet (low calcium and vitamin D3 intake), 
undernutrition and also excessive exercises [45]. Excessive 
exercise (exercise-related hypothalamic amenorrhea) does 
not improve bone mass density (BMD), but leads to osteo-
penia [46]. Hormonal factors responsible for a decrease of 
bone mass density are as follows: low serum IGF-I, insu-
lin and high serum cortisol [42]. Generally, the degree of 
BMD decrease in FHA patients is less expressed than in 
patients with anorexia nervosa [47, 48].
It is important to stress that the female sex per se is 
more prone to have osteopenia or osteoporosis because the 
optimal PBM reached by females is 25–30 % lower than 
in males [49]. Reduction of PBM increases the risk of a 
decreased bone mass density during the pubertal period, 
as well as in the fertile and perimenopausal periods, which 
results in a major risk of pathological fractures [40].
Podfigurna-Stopa et al. [50] have estimated the skeletal 
status and body composition of young women with func-
tional hypothalamic amenorrhea. FHA individuals had a 
decreased fat tissue mass and an imbalanced relationship 
between body weight, fat tissue mass and lean body mass. 
Despite the reduced BMD and bone mineral content, FHA 
did not, however, significantly affect bone strength.
According to the International Society for Clinical 
Densitometry, amenorrhea related to hypoetrogenism last-
ing 6 months is the indication to perform a densitometry 
(DEXA) of the spinal column [51]. This has an important 
clinical aspect because FHA as a disorder of the hypotha-
lamic–pituitary axis is the main entity responsible for BMD 
decrease in young women [52].
More attention should be paid to exercise among 
women. For most of the young women, exercise causes a 
positive effect—improving health and physical fitness. 
However, if the exercise energy expenditure increases more 
than energy intake, a variety of clinical manifestations can 
occur. Such sports as ballet dancing, running, or gymnas-
tics may lead to poor nutritional behaviors, resulting in low 
energy availability. Abnormally low BMD and osteoporo-
sis in exercising women relate to premature bone loss and 
microarchitectural deterioration. Mainly, female athletes 
with amenorrhea are at increased risk for stress fractures 
and skeletal fragility [53].
Cardiovascular system
Cardiovascular disease (CVD) is the leading cause of death 
in women in developed countries and, interestingly, propor-
tionally more women die from CVD than men.
As it is known, hypoestrogenism can interfere with the 
cardiovascular system function in many ways. Coronary 
and peripheral vessels contain estrogen receptors that per-
mit estradiol to play a regulatory role in vascular function. 
Estrogen excites the synthesis of nitric oxide (NO) through 
both genomic and nongenomic effects, leading to the 
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augmented production of endothelial-derived NO, causing 
vasodilatation [54].
Estradiol exerts a positive, cardioprotective effect 
through its influence on the endothelial, myocardial and 
vascular function and metabolic parameters [55]. In con-
trast, hypoestrogenism can lead to endothelial dysfunction, 
an impaired bioactivity of nitric oxide, perturbation in auto-
nomic function, activation of the rennin–angiotensin sys-
tem and lipid profile changes [56].
These physiological and pathological phenomena are 
reflected in clinical studies. Several investigators have dem-
onstrated a correlation between FHA and endothelial dys-
function [57]. It was clearly shown that the flow-mediated 
dilation of the brachial artery (which is a precise predic-
tor of coronary endothelial dysfunction) is impaired in 
women with FHA [51]. It is suggested that the decrease of 
endothelial NO bioavailability is caused by chronic estro-
gen deficiency. Moreover, some authors have proved the 
protective effect of exogenous estrogens in young women 
against impaired vessels’ dilatation. Rickenlund et al. [58] 
documented significantly increased brachial artery dilata-
tion after 9 months of treatment with low-dose combined 
contraceptives (30 µg of ethinyl estradiol and 150 µg of 
levonorgestrel): from 1.42 ± 0.98 % before treatment to 
4.88 ± 2.20 % during treatment.
A Women’s Ischemia Syndrome Evaluation (WISE) 
study found a significant association between premenopau-
sal angiographic coronary artery disease (CAD) and hypo-
thalamic hypogonadism [59]. O’Donnell et al. [60] recently 
showed that young athletes with chronic hypoestrogenemia 
displayed an impaired peripheral vascular function that was 
combined with lower resting blood pressures and heart rate 
and reduced ischemic responses to occlusion challenge 
compared to ovulatory women.
Impaired cardiovascular function in hypothalamic amen-
orrhea is believed to be linked mainly to hypoestrogenism, 
but it is also aggravated by negative energy balance and 
metabolic disturbances. Patients with FHA are character-
ized by an impaired lipid profile and are at risk of glucose 
metabolism abnormalities. Women with exercise-related 
amenorrhea present higher serum total cholesterol, LDL 
cholesterol, apolipoprotein B and triglyceride concentra-
tions than healthy individuals [61, 62]. On the other hand, 
premenopausal women with hypoestroegism of hypotha-
lamic origin present an increased frequency of diabetes 
mellitus. Moreover, Ahmed et al. [63] showed that coro-
nary artery disease (detected in coronarography) has an 
increased prevalence and extent among women with dia-
betes and hypothalamic hypoestrogenism in comparison to 
women with diabetes alone.
These observations substantiate the importance of 
cyclic ovarian function as an indicator of cardiovascu-
lar health. However, the influence of hypoestrogenism in 
young women of hypothalamic origin on cardiovascular 
health requires further studies. Especially the issue of the 
long-term consequences of FHA on CVD risk needs to 
be cleared to possibly minimize the risk of cardiovascular 
events in this group of women.
Mental and sexual dysfunction
Mood in women in its essential part is linked to serum sex 
steroid levels, particularly estrogen [64]. Hypoestrogenism 
in young women with FHA is strongly related to changes 
in different neuropeptides, neurotransmitters and neuro-
steroids activity at the brain level. Specifically, serotonin, 
dopamine and allopregnanolone fluctuations can modulate 
mood in amenorrheic women [65]. The number of studies 
concerning this subject is very limited. FHA patients pre-
sent a specific psychological profile.
Gilles and Berga [66] assessed the association of cog-
nitive function and emotional and psychiatric history in 
women with functional hypothalamic amenorrhea com-
pared with amenorrheic and eumenorrheic controls. 
Women with FHA endorsed more dysfunctional attitudes, 
had greater difficulty in coping with daily stresses and 
tended to endorse greater interpersonal dependence than 
eumenorrheic women.
Hypercortisolemia is one of the characteristic hormonal 
features of FHA patients. Serum cortisol levels positively 
correlate with the Hamilton Rating Scale for Depression 
and Anxiety, and hypercortisolemia can be regarded as a 
possible mediator of mood disturbances [67]. FHA patients 
present a particular susceptibility to common life events, 
restrictive disordered eating, depressive traits and psycho-
somatic disorders [68].
Bomba et al. [69] reported that patients with FHA and 
AN present common psychopatological aspects. These 
include maturity issues, social insecurity and introversion, 
a tendency to depression, excessive concerns with dieting 
and the fear of gaining weight.
Sexual functioning is also of important significance 
for FHA patients. Dundon et al. [70] found that women 
with FHA have more sexual problems than healthy con-
trols. Theoretically, this functioning is determined by the 
psychological and hormonal background. Psychological 
problems are aggravated by the fact that FHA is associ-
ated with anxiety, depressive symptoms and high rates of 
mood disorders [71]. The mediating effects of anxiety and 
depression may explain the occurrence of sexual dysfunc-
tion which is potentially associated with FHA. Although 
they were significantly higher in FHA subjects, out of the 
two, only depression offered a plausible explanation for 
sexual difficulties FHA subjects typically face. Due to the 
objective difficulties of correlating hormonal measurements 
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with psychometric data, it remains uncertain whether such 
an association can result from a common neuroendocrine 
background. Furthermore, it cannot be stated that anxiety 
(and not depression) influences sexual function differently 
in FHA subjects [72].
The hormonal background of sexual dysfunction in FHA 
may be related to profound hypoestrogenism and hypoan-
drogenemia [72, 73]. It can be related to genital tract status 
and sexual drive.
Conclusions
FHA is an underestimated clinical problem. It is related to 
profound impairment of reproductive functions including 
anovulation and infertility. Women’s health in this disorder 
is disturbed in several aspects including their skeletal sys-
tem, cardiovascular system and mental problems. Patients 
manifest a decrease of bone mass density, which is related 
to an increase of fracture risk. Therefore, osteopenia and 
osteoporosis are the main long-term complications of FHA. 
Cardiovascular complications include endothelial dys-
function and abnormal changes in the lipid profile. FHA 
patients present significantly higher depression and anxiety 
and also sexual problems compared to healthy subjects.
FHA patients should be carefully diagnosed and prop-
erly managed to prevent both short- and particularly long-
term medical consequences.
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